General form of registration statement for all companies including face-amount certificate companies

3. Significant Strategic Drug Development Collaborations (Details Narrative)

v3.19.2
3. Significant Strategic Drug Development Collaborations (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Revenue $ 0 $ 7,585,000
Licenses [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Revenue $ 0 $ 7,500,000
Serum Institute of India Ltd [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Percent ownership in Xenetic 6.70% 7.20%
Pharmsynthez [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Percent ownership in Xenetic 57.10% 61.50%
Pharmsynthez [Member] | Series B Preferred Stock [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Common stock outstanding 1,500,000  
Pharmsynthez [Member] | Series A Preferred Stock [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Common stock outstanding 970,000  
Research, development, license and supply agreement [Member] | Takeda [Member] | Licenses [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Revenue   $ 7,500,000
Research, development, license and supply agreement [Member] | SynBio [Member] | Co-Development Agreement [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Revenue $ 0 0
License and supply agreements [Member] | Serum Institute of India Ltd [Member] | Royalty Revenue [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Revenue $ 0 $ 0